VIM and neoplasm: Regarding immunohistochemistry, the tumor tended to be positive for vimentin (100%; n = 35/35), CD34 (63.4%; n = 26/41), ER (50%; n = 16/32), and PR (53.3%; n = 16/30), while S-100 showed 91% negativity (n = 41/45).